35 results about "Trypanosoma" patented technology

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

Herein disclosed are rapid real-time isothermal multiplex methods of detecting, identifying and quantifying bacterial, viral, and protozoan nucleic acids in a sample. These include contacting the sample with two or more sets of pathogen-specific reverse transcription loop-mediated isothermal amplification primers and novel oligofluorophores specific for the target bacterial, viral, and parasitic nucleic acids of interest such as human immunodeficiency virus, Ebola virus, Marburg virus, Yellow fever virus, hepatitis-B virus, Lassa fever virus, Plasmodium, hepatitis-C virus, hepatitis-E virus, dengue virus, Chikungunya virus, Japanese Encephalitis virus, Middle Eastern Respiratory Syndrome Corona virus, Mycobacterium, West Nile virus, Cytomegalovirus, Parvovirus, Leishmania, Trypanosoma, and Zika virus nucleic acids, under conditions sufficient to produce detectable real-time amplification signals in about 10 to 40 minutes. The amplification signals are produced by pathogen-specific fluorogenic labels included in one or more of the primers. Also, novel reaction and sample lysis buffers, primers, and kits for rapid multiplex detection, quantification, and identification of bacterial, viral, and protozoan nucleic acids by real-time isothermal amplification are herein disclosed.

The use of alkyl quaternary ammonium compounds including certain choline analogs for treating or preventing fungal and trypanosomal (e.g., Leishmaniasis) infections is described. These compounds, characterized as mono- and bis-alkyl ammonium compounds, were demonstrated to be highly effective in inhibiting growth of Candida albicans, Saccharomyces cerevisiae and Leishmania major. Quaternary ammonium compounds were previously known as effective antimalarial compounds in vivo but not recognized as antifungals or as anti-trypanosomals (e.g., anti-Leishmanials).

Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.

It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.

The present invention provides cell free preparations of protozoan microsomes, wherein the cell free preparation of protozoan microsomes demonstrate the ability to translocate a protozoan polypeptide into the microsome, methods of preparing cell free preparations of protozoan microsomes, and methods of using cell free preparations of protozoan microsomes.

A compound represented by formula (I): [wherein, for example, X is a hydrogen atom or a halogen atom; R1 is a hydrogen atom; R2 is a hydrogen atom or a C1-4 alkyl group; R3 is —CHO or —COOH; and R4 is —CH═CH—(CH2)p—CH3 (wherein p is an integer of 1 to 12), —CH(OH)—(CH2)q—CH3 (wherein q is an integer of 1 to 13), —CH(OH)—CH2—CH(CH3)—(CH2)2—CH═C(CH3)2, —CH═CH—CH(CH3)—(CH2)3—CH(CH3)2, —(CH2)2—CH(CH3)—(CH2)3—CH(CH3)2 or —(CH2)8—CH3], an optical isomer thereof and a pharmaceutically acceptable salt thereof. These compounds have antitrypanosoma activity, and accordingly are useful as drugs for preventing or treating the diseases caused by trypanosoma.

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei. The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and / or a deletion of N388 and Y389 to the subject.

Methods for delivering potentially therapeutic or prophylactic protein and peptide agents to mammalian cells are provided. The agents are delivered by mutant trypanosomatid protozoa that have been genetically manipulated to code for such protein or peptide agents. The mutant protozoa additionally lack certain enzymes within the heme biosynthetic pathway, making the mutants susceptible to porphyria and eventual lysis.

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

The present invention provides novel enzymes, tryparedoxins, their isolation from Crithidia fasciculata, a method for the production thereof in genetically transformed bacteria, and their use as molecular targets for the discovery of trypanocidal drugs

The present invention provides cell free preparations of protozoan microsomes, wherein the cell free preparation of protozoan microsomes demonstrate the ability to translocate a protozoan polypeptide into the microsome, methods of preparing cell free preparations of protozoan microsomes, and methods of using cell free preparations of protozoan microsomes.

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei. The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and / or a deletion of N388 and Y389 to the subject.

A compound represented by formula (I):[wherein, for example,X is a hydrogen atom or a halogen atom;R1 is a hydrogen atom;R2 is a hydrogen atom or a C1-4 alkyl group;R3 is —CHO or —COOH; andR4 is —CH═CH—(CH2)p—CH3 (wherein p is an integer of 1 to 12), —CH(OH)—(CH2)q—CH3 (wherein q is an integer of 1 to 13), —CH(OH)—CH2—CH(CH3)—(CH2)2—CH═C(CH3)2, —CH═CH—CH(CH3)—(CH2)3—CH(CH3)2, —(CH2)2—CH(CH3)—(CH2)3—CH(CH3)2 or —(CH2)8—CH3], an optical isomer thereof and a pharmaceutically acceptable salt thereof. These compounds have antitrypanosoma activity, and accordingly are useful as drugs for preventing or treating the diseases caused by trypanosoma.

The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and trypanosoma infections, bacterial infections such as S. aureus and C. albicans, and cancers such as breast, colon, lung, or prostate cancer. The invention further provides methods of synthesizing such compounds as well as kits useful for administering the compounds.

The present invention relates to a class of novel pradimicins and analogues and derivatives thereof, including the compounds of formula A, I and 111, and / or a pharmaceutical acceptable addition salt thereof and / or a stereoisomer thereof and / or a solvate thereof and their use to treat or prevent kinetoplastid infections and their use to manufacture a medicine to treat or prevent kinetoplastid infections, particularly infections with trypanosoma and leishmania, such as Trypanosoma brucei, Trypanosoma cruzi and Leischmania donovani. wherein Ra, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claim 1 or as described in detail in the description of the invention. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent kinetoplastid infections. The present invention further relates active ingredients, more specifically as medicaments for the treatment of kinetoplastid infections and pathologic conditions such as, but not limited to Trypanosomiasis, such as African trypanosomiasis, sleeping sickness, Chagas disease and leishmaniasis.

Compounds derived from imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides, for use as a drug or pharmaceutical composition for treatment of parasitic diseases, preferably of diseases caused by parasites of the Trypanosoma genus, and more preferably for treatment of the Chagas disease. Furthermore, the invention also relates to the pharmaceutical compositions comprising said compounds.

The invention relates to a new use of diphenyleneiodonium (DPI) as an active substance against parasites of the family Trypanosomatidae, in particular against parasites of the genus Leishmania and Trypanosoma.

The present invention provides the application of 17-ketosteroids and their derivatives, metabolites and precursors and pharmaceutically acceptable salts of these compounds in the treatment of malaria, African trypanosomiasis and American trypanosomiasis, or in alleviating or alleviating a certain For the application of one or more symptoms associated with malaria parasite or trypanosome infection, the above-mentioned compounds are collectively referred to as "compounds of the present invention". The present invention further relates to the use of said compounds in the treatment or prevention of one or more parasites and / or one or more diseases caused by said parasites, against one or more mycoplasma and / or one or more A disease caused by said mycoplasma, and / or against one or more of the following indications or infections and all other indications and infections: (a) hairy leukoplakia, (b) oral candidiasis, (c) Mouth ulcers - aphthous / herpetic / bacterial, (d) fungal candida, (e) human papillomavirus, (f) molluscum contagiosum, (g) squamous oral carcinoma, (h) ) Kaposi's sarcoma oral lesions, (i) periodontitis, (j) necrotizing gingivitis, (k) orofacial herpes zoster, and (l) rotavirus. The compounds of the invention may also be used to alleviate or lessen one or more symptoms associated with the infections or diseases described herein.

Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1).

The invention discloses a grouper pyramidal detection primer group, a kit, a detection method and application, the detection method comprises two rounds of PCR (polymerase chain reaction) amplification, the upstream outer primer of the first round of amplification is 5 '-GAAACGC CAAGCTAATACATG-3', the downstream outer primer of the first round of amplification is 5 '-ACCATATGGAAACAACG-3', the upstream inner primer of the second round of amplification is 5 '-GACGAACAACATGCCCTATCAA-3', and the downstream inner primer of the second round of amplification is 5 '-CGCATCCTGGGTAA-3'. According to the invention, various defects of the existing detection means are overcome, high-sensitivity, high-specificity, rapid and convenient detection of the grouper pyramidal worm is realized, and powerful technical support is provided for timely prevention and control of diseases and reduction of economic loss in the grouper breeding industry.

The invention discloses a primer pair and kit for detecting a mouse trypanosome. By comparing a macrocyclic sequence of the mouse trypanosome with macrocyclic sequences of other similar trypanosomes, one primer pair TM2-F and TM2-R which can specifically detect the mouse trypanosome is screened, and sequences of the primer pair are shown in SEQ ID NO:1 and SEQ ID NO:2; the primer pair can specifically amplify a partial segment of the mouse trypanosome, is high in sensitivity and can detect a sample which contains 10 trypanosomes only or 1 ng DNA sample; and by utilizing the primer pair, the mouse trypanosome can be rapidly and accurately identified from other trypanozoons and leishmania amazonesis without an expensive microscope and professional etiology knowledge, detection is quick and convenient, and the primer pair can be used for detecting early infection, is also applicable to detection of animal trypanosome mixed infection, is beneficial to development of epidemiological investigation and can be applicable to detection of human mouse trypanosome infection.

A therapeutic agent for treating a Trypanosoma-associated disease; a method of preventing infection by Trypanosoma parasites, or killing Trypanosoma parasites; and use thereof, the therapeutic agent and the method each using a mechanism different from a mechanism used in conventional technology. The therapeutic agent of the present invention for treating a Trypanosoma-associated disease includes, as a medicinal component, an antisense oligonucleotide suppressing the expression of an inositol 1,4,5-trisphosphate receptor protein of Trypanosoma parasites.

A method for in vivo passage culture of a large yellow croaker Trypanosoma in a grouper, belonging to the field of aquatic animal disease prevention and control and microorganism technology, comprising: 1) preparing an infection source containing the large yellow croaker Trypanosoma; 2) inoculating the infection source into a healthy grouper; 3) feeding the inoculated grouper to make the Trypanosoma proliferate in the grouper; and 4) separating the amplified large yellow croaker Trypanosoma from the grouper. The method aims to realize stable amplification and continuous passage of the large yellow croaker Trypanosoma by using the grouper as a substitute host, and to provide stable and reliable worm source guarantee for related scientific research and production application.

Polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA are provided. Specifically, the present invention can be used to downregulate snoRNA molecules or box H / ACA-containing RNA molecules which are involved in diseases such as cancer.

The present invention relates to methods and compositions for preventing, treating and diagnosing infection by trypanosomes. The invention also relates to the use of excreted / secreted antigens (exoantigens, secretome) and specifically to the identification of a protein excreted / secreted by the trypanosomes, the inhibition of which makes it possible to provide effective protection, mainly by vaccination, against infection by trypanosomes or the development or spread thereof. The invention relates to use of the protein, the derivatives thereof, a nucleotide sequence derived from said protein, or an extract enriched with said protein, and to the use of antibodies directed against said trypanosomes for immunotherapy, diagnosis, and monitoring of infections by trypanosomes.

An antibody was raised against a synthetic 27 per peptide (ProEP2-1) blocked T. brucei and ProEP2-1-induced apoptosis in human brain vascular endothelial cells (HBVEC). The use of this and similar blocking antibodies have use both as diagnostic agents and in treatment to prevent damage arising from infection.

The invention relates to a new use of diphenyleneiodonium (DPI) as an active substance against parasites of the family Trypanosomatidae, in particular against parasites of the genus Leishmania and Trypanosoma.